* age \<18 years; age \>80 years * pregnant or breast feeding woman * patient in other therapeutic clinical trial within 30 days before icf * receive any other ace inhibitors (acei), angiotensin-receptor blockers (arb) treatment within 7 days before icf * chronic immunosuppression: current autoimmune diseases or patients who received immunotherapy within 30 days before icf * hematologic malignancy (lymphoma, leukemia, multiple myeloma) * other patient characteristics (not thought to be related to underlying covid-19) that portend a very poor prognosis (e.g, severe liver failure, and ect) * known allergy to study drug or its ingredients related to renin-angiotensin system (ras), or frequent and/or severe allergic reactions with multiple medications * other uncontrolled diseases, as judged by investigators * body weight ≥85 kg * hypercholesterolemia * hypertriglyceridemia * liver disease * renal disease * sjögren syndrome * pregnancy * lactation * depressive disorder * contraindications for hormonal contraception or intrauterine device. * autoimmune diseases a history of organ, bone marrow or hematopoietic stem cell transplantation * patients receiving anti-hcv treatment * permanent blindness in one eye * history of iritis, endophthalmitis, scleral inflammation or retinitis 15-90 days of retinal detachment or eye surgery * the competent physician considered it inappropriate to participate in the study

* age \<18 years; age \>80 years * pregnant or breast feeding woman * patient in other therapeutic clinical trial within 30 days before icf * receive any other ace inhibitors (acei), angiotensin-receptor blockers (arb) treatment within 7 days before icf * chronic immunosuppression: current autoimmune diseases or patients who received immunotherapy within 30 days before icf * hematologic malignancy (lymphoma, leukemia, multiple myeloma) * other patient characteristics (not thought to be related to underlying covid-19) that portend a very poor prognosis (e.g, severe liver failure, and ect) * known allergy to study drug or its ingredients related to renin-angiotensin system (ras), or frequent and/or severe allergic reactions with multiple medications * other uncontrolled diseases, as judged by investigators * body weight ≥85 kg * hypercholesterolemia * hypertriglyceridemia * liver disease * renal disease * sjögren syndrome * pregnancy * lactation * depressive disorder * contraindications for hormonal contraception or intrauterine device. * autoimmune diseases a history of organ, bone marrow or hematopoietic stem cell transplantation * patients receiving anti-hcv treatment * permanent blindness in one eye * history of iritis, endophthalmitis, scleral inflammation or retinitis 15-90 days of retinal detachment or eye surgery * the competent physician considered it inappropriate to participate in the study

- age <18 years; age >80 years - pregnant or breast feeding woman - patient in other therapeutic clinical trial within 30 days before icf - receive any other ace inhibitors (acei), angiotensin-receptor blockers (arb) treatment within 7 days before icf - chronic immunosuppression: current autoimmune diseases or patients who received immunotherapy within 30 days before icf - hematologic malignancy (lymphoma, leukemia, multiple myeloma) - other patient characteristics (not thought to be related to underlying covid-19) that portend a very poor prognosis (e.g, severe liver failure, and ect) - known allergy to study drug or its ingredients related to renin-angiotensin system (ras), or frequent and/or severe allergic reactions with multiple medications - other uncontrolled diseases, as judged by investigators - body weight ≥85 kg - hypercholesterolemia - hypertriglyceridemia - liver disease - renal disease - sjögren syndrome - pregnancy - lactation - depressive disorder - contraindications for hormonal contraception or intrauterine device. - autoimmune diseases a history of organ, bone marrow or hematopoietic stem cell transplantation - patients receiving anti-hcv treatment - permanent blindness in one eye - history of iritis, endophthalmitis, scleral inflammation or retinitis 15-90 days of retinal detachment or eye surgery - the competent physician considered it inappropriate to participate in the study

- age <18 years; age >80 years - pregnant or breast feeding woman - patient in other therapeutic clinical trial within 30 days before icf - receive any other ace inhibitors (acei), angiotensin-receptor blockers (arb) treatment within 7 days before icf - chronic immunosuppression: current autoimmune diseases or patients who received immunotherapy within 30 days before icf - hematologic malignancy (lymphoma, leukemia, multiple myeloma) - other patient characteristics (not thought to be related to underlying covid-19) that portend a very poor prognosis (e.g, severe liver failure, and ect) - known allergy to study drug or its ingredients related to renin-angiotensin system (ras), or frequent and/or severe allergic reactions with multiple medications - other uncontrolled diseases, as judged by investigators - body weight ≥85 kg - hypercholesterolemia - hypertriglyceridemia - liver disease - renal disease - sjögren syndrome - pregnancy - lactation - depressive disorder - contraindications for hormonal contraception or intrauterine device. - autoimmune diseases a history of organ, bone marrow or hematopoietic stem cell transplantation - patients receiving anti-hcv treatment - permanent blindness in one eye - history of iritis, endophthalmitis, scleral inflammation or retinitis 15-90 days of retinal detachment or eye surgery - the competent physician considered it inappropriate to participate in the study